Eric J. Velazquez
Yale University
Internal medicineSurgeryCardiologyRandomized controlled trialIntensive care medicineHazard ratioIschemic cardiomyopathyArteryValsartanHeart failureCoronary artery diseaseMyocardial infarction complicationsHeart diseasePopulationIn patientMyocardial infarctionProportional hazards modelMedicineEjection fractionBlood pressure
Publications 509
#1Stephen J. GreeneH-Index: 38
#2Eric J. VelazquezH-Index: 79
Last. Robert J. MentzH-Index: 53
view all 5 authors...
#1Rohan Khera (Yale University)H-Index: 27
#2Yusi Liu (Yale University)
Last. Christine Rutan (AHA: American Heart Association)H-Index: 3
view all 18 authors...
Background null Whether the volume of coronavirus disease-19 (COVID-19) hospitalizations is associated with outcomes has important implications for the organization of hospital care both during this pandemic and also future novel and rapidly evolving high-volume conditions. null Methods null We identified COVID-19 hospitalizations at US hospitals in the American Heart Association COVID-19 Cardiovascular Disease Registry with ≥10 cases between January and August 2020. We evaluated the association...
#1Evangelos Oikonomou (Yale University)H-Index: 32
#2David van Dijk (Yale University)H-Index: 23
Last. Rohan Khera (Yale University)H-Index: 27
view all 9 authors...
AIMS Coronary artery disease is frequently diagnosed following evaluation of stable chest pain with anatomical or functional testing. A more granular understanding of patient phenotypes that benefit from either strategy may enable personalized testing. METHODS AND RESULTS Using participant-level data from 9572 patients undergoing anatomical (n = 4734) vs. functional (n = 4838) testing in the PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) trial, we created a topologi...
3 CitationsSource
#1Fouad Chouairi (Yale University)H-Index: 5
#2Michael Fuery (Yale University)H-Index: 2
Last. P. Elliott Miller (Yale University)H-Index: 13
view all 19 authors...
Background null It remains unclear why depression is associated with adverse outcomes in heart failure (HF) patients. We examine the relationship between depression and clinical outcomes among patients with HF and reduced ejection fraction (HFrEF) managed with guideline directed medical therapy (GDMT). null Methods null Using the GUIDE-IT trial, 894 patients with HFrEF were stratified according to a history of depression, and Cox proportional hazards regression modeling was used to examine the a...
Background: Coronavirus disease 2019 (COVID-19) can cause cardiac injury resulting in abnormal right or left ventricular function (RV/LV) with worse outcomes. We hypothesized that two-dimensional (2D) speckle-tracking assessment of LV global longitudinal strain (GLS) and RV free wall strain (FWS) by transthoracic echocardiography can assist as markers for subclinical cardiac injury predicting increased mortality. Methods: We performed 2D strain analysis via proprietary software in 48 patients ho...
#1Tariq Ahmad (Yale University)H-Index: 69
#2Yu Yamamoto (Yale University)H-Index: 6
Last. F. Perry Wilson (Yale University)H-Index: 22
view all 11 authors...
Heart failure (HF) is one of the most common causes of hospitalization in the United States and carries a significant risk of morbidity and mortality. Use of evidence-based interventions may improve outcomes, but their use is encumbered in part by limitations in accurate prognostication. The REVeAL-HF (Risk EValuation And its Impact on ClinicAL Decision Making and Outcomes in Heart Failure) trial is the first to definitively evaluate the impact of knowledge about prognosis on clinical decision m...
#1Abhinav Sharma (MUHC: McGill University Health Centre)H-Index: 23
#2Stephen J. Greene (Duke University)H-Index: 38
Last. G. Michael Felker (Duke University)H-Index: 94
view all 15 authors...
AIMS Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the 'Functional Impact of GLP-1 for Heart Failure Treatment' (FIGHT) study to address these knowledge gaps. METHODS AND RESULTS FIGHT was a randomized clinical trial testing the effect of liraglutide (vs. placebo) among 300...
#1Robert D. Brook (UM: University of Michigan)H-Index: 64
#2Niko Kaciroti (UM: University of Michigan)H-Index: 54
Last. Accomplish investigatorsH-Index: 1
view all 8 authors...
BACKGROUND The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to <130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI). METHODS In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypert...
2 CitationsSource
#1Avirup Guha (Case Western Reserve University)H-Index: 12
#2Cesar Caraballo (Yale University)H-Index: 7
Last. Nihar R. Desai (Yale University)H-Index: 25
view all 12 authors...
AIMS Improved cancer survivorship has led to a higher number of anthracycline-induced cardiomyopathy patients with end-stage heart failure. We hypothesize that outcomes following continuous-flow LVAD (CF-LVAD) implantation in those with anthracycline-induced cardiomyopathy are comparable with other aetiologies of cardiomyopathy. METHODS AND RESULTS Using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) from 2008 to 2017, we identified patients with anthracycline...